- Home
- BRLT vs AYTU Comparison
BRLT vs AYTU Comparison
Compare BRLT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- AYTU
- Stock Information
- Founded
- BRLT 2005
- AYTU N/A
- Country
- BRLT United States
- AYTU United States
- Employees
- BRLT N/A
- AYTU N/A
- Industry
- BRLT Consumer Specialties
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- AYTU Health Care
- Exchange
- BRLT Nasdaq
- AYTU Nasdaq
- Market Cap
- BRLT 19.8M
- AYTU 19.7M
- IPO Year
- BRLT 2021
- AYTU N/A
- Fundamental
- Price
- BRLT $2.36
- AYTU $2.32
- Analyst Decision
- BRLT Hold
- AYTU Strong Buy
- Analyst Count
- BRLT 2
- AYTU 2
- Target Price
- BRLT $1.80
- AYTU $10.00
- AVG Volume (30 Days)
- BRLT 306.9K
- AYTU 78.1K
- Earning Date
- BRLT 11-06-2025
- AYTU 11-12-2025
- Dividend Yield
- BRLT 10.50%
- AYTU N/A
- EPS Growth
- BRLT N/A
- AYTU N/A
- EPS
- BRLT N/A
- AYTU N/A
- Revenue
- BRLT $422,218,000.00
- AYTU $81,659,000.00
- Revenue This Year
- BRLT $5.55
- AYTU N/A
- Revenue Next Year
- BRLT $3.88
- AYTU $2.00
- P/E Ratio
- BRLT N/A
- AYTU N/A
- Revenue Growth
- BRLT N/A
- AYTU 0.41
- 52 Week Low
- BRLT $1.25
- AYTU $0.95
- 52 Week High
- BRLT $3.10
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- BRLT 49.28
- AYTU 51.60
- Support Level
- BRLT $2.75
- AYTU $2.21
- Resistance Level
- BRLT $2.70
- AYTU $2.38
- Average True Range (ATR)
- BRLT 0.28
- AYTU 0.12
- MACD
- BRLT -0.07
- AYTU 0.01
- Stochastic Oscillator
- BRLT 26.00
- AYTU 57.69
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.